Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 8/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | CTSB | P07858 | 2/20 | 0.32 |
| ▸ | CTSH | P09668 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17346684 | 1.00 | DPP7 (0.40) | DPP7DPP4DPP8DPP9CTSK | |
| SCHEMBL20806774 | 0.88 | SIRT6 (0.40) | DPP7DPP4DPP8DPP9SMN1; SMN2 | |
| SCHEMBL17637509 | 0.85 | DPP4 (0.42) | DPP7DPP4DPP8DPP9CTSK | |
| SCHEMBL17740076 | 0.85 | DPP4 (0.42) | DPP7DPP4DPP8DPP9CTSK | |
| SCHEMBL17867378 | 0.83 | SMN1; SMN2 (0.39) | DPP7DPP4DPP8DPP9CTSK | |
| SCHEMBL17867376 | 0.83 | SMN1; SMN2 (0.39) | DPP7DPP4DPP8DPP9CTSK | |
| SCHEMBL19576288 | 0.83 | SMN1; SMN2 (0.38) | CTSKCASP1SMN1; SMN2CTSLCTSB | |
| SCHEMBL22788848 | 0.83 | SMN1; SMN2 (0.38) | CTSKCASP1SMN1; SMN2CTSLCTSB | |
| SCHEMBL18522853 | 0.83 | SMN1; SMN2 (0.38) | CTSKCASP1SMN1; SMN2CTSLCTSB | |
| SCHEMBL23221289 | 0.83 | DPP4 (0.40) | DPP7DPP4DPP8DPP9CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287047-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | BICYCLETX LIMITED (GB) | 2023-09-14 | — | — | US | disclosed |
| WO-2020252015-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | SUTRO BIOPHARMA, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252043-A1 | 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF | SUTRO BIOPHARMA, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2018127699-A1 | COMPOUNDS FOR TREATING CANCER | Bicyclerd Limited (GB) | 2018-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287047-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | NECTIN4, VCAM1, SIGLEC7 | DPP7 387/4885DPP4 112/4885DPP8 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.